|1.||Scheinberg, David A: 1 article (01/2003)|
|2.||Philips, Mark R: 1 article (01/2003)|
|3.||Rosenblum, Michael G: 1 article (01/2003)|
|4.||McGrath, Melissa S: 1 article (01/2003)|
|1.||Myeloid Leukemia (Leukemia, Myelocytic)
02/01/1996 - "These data show that HuM195-rGel can target leukemia cells in vivo and can result in pronounced anti-leukemic effects."
02/01/1996 - "HuM195-rGel was found to target leukemia cells rapidly in vivo and was subsequently internalized into the cells. "
01/01/2003 - "K562 leukemia cells retrovirally infected to overexpress P-gp are also resistant to HuM195-gelonin. "
02/01/1996 - "HuM195-rGel demonstrated significant tumor suppressive activity in this model. "
02/01/1996 - "While all mice treated with either saline, rGel alone, or HuM195 plus unconjugated rGel (at 10 or 14 days after transplantation) had rapid tumor growth or early deaths, 50% of mice treated with HuM195-rGel failed to develop leukemic tumors for 5 months and the 50% had significantly retarded tumor growth after treatment with HuM195-rGel. "
|3.||Dihydrotachysterol (AT 10)
|1.||Transplantation (Transplant Recipients)